First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

被引：0
|
作者：
Even, C. [1 ]
Torossian, N. [2 ]
Ibrahim, T. [3 ]
Martin, N. [4 ]
Badis, L. Mayache [1 ]
Ferrand, F. R. [5 ]
Iacob, M. [1 ]
Guigay, J. [6 ]
Le Tourneau, C. [2 ]
Daste, A. [7 ]
Saada-Bouzid, E. [4 ]
Saleh, K. [1 ]
机构：
[1] Gustave Roussy Canc Ctr, Head & Neck Oncol Dept, Villejuif, France
[2] Inst Curie, Med Oncol, Paris, France
[3] Gustave Roussy, Med Oncol, Canc Campus, Villejuif, France
[4] Ctr Anticanc Antoine Lacassagne, Dept Med Oncol, Nice, France
[5] Begin Mil Teaching Hosp, Med Oncol, St Mande, France
[6] Ctr Anticanc Antoine Lacassagne, Med Oncol Direct, Nice, France
[7] CHU Bordeaux, Hop St Andre, Gironde, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1138P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    El Rassy, Elie
    Assi, Tarek
    Bakouny, Ziad
    El Karak, Fadi
    Pavlidis, Nicholas
    Ghosn, Marwan
    FUTURE ONCOLOGY, 2019, 15 (08) : 909 - 924
  • [2] Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Ho, Alan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (04) : 736 - +
  • [3] Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Borcoman, Edith
    Marret, Gregoire
    Le Tourneau, Christophe
    CANCERS, 2021, 13 (11)
  • [4] Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma
    Weiss, Jared M.
    Bagley, Stephen
    Hwang, Wei-Ting
    Bauml, Joshua
    Olson, Juneko Grilley
    Cohen, Roger B.
    Hayes, David Neil
    Langer, Corey
    CANCER, 2016, 122 (15) : 2350 - 2355
  • [5] Weekly docetaxel as second-line (palliative) chemotherapy in recurrent/ metastatic head and neck squamous cell carcinoma (SCCHN)
    Koussis, H.
    Scola, A.
    Bergamo, F.
    Tonello, S.
    Jirillo, A.
    Basso, U.
    Pasetto, L. M.
    Sperandio, P.
    Donach, M. E.
    Monfardini, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] FIRST- AND SECOND-LINE TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: A CHART REVIEW STUDY IN THREE COUNTRIES
    Gogate, A.
    Shillington, A. C.
    Dave, V
    Singh, P.
    VALUE IN HEALTH, 2022, 25 (12) : S287 - S287
  • [7] Second-line chemotherapy for metastatic/recurrent head and neck cancer
    Ferrari, D.
    Codeca, C.
    Caldiera, S.
    Zonato, S.
    Luciani, A.
    Fiore, J.
    Cossu-Rocca, M.
    Verri, E.
    Foa, P.
    ANNALS OF ONCOLOGY, 2007, 18 : 56 - 56
  • [8] Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck
    Yokoyama, Kazuki
    Wasano, Koichiro
    Sasaki, Keita
    Machida, Ryunosuke
    Nakahira, Mitsuhiko
    Kitamura, Koji
    Sakagami, Tomofumi
    Takeshita, Naohiro
    Ohkoshi, Akira
    Suzuki, Motoyuki
    Tateya, Ichiro
    Morishita, Yohei
    Sekimizu, Mariko
    Nakayama, Masahiro
    Koyama, Taiji
    Shibata, Hirofumi
    Miyamaru, Satoru
    Kiyota, Naomi
    Hanai, Nobuhiro
    Homma, Akihiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (10) : 1115 - 1122
  • [9] Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
    Bernier, Jacques
    ONCOLOGY REVIEWS, 2009, 3 (04) : 247 - 256
  • [10] Efficacy and safety of apatinib as second-line or beyond therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Qin, You
    Ding, Qian
    Xu, Xinhua
    Cao, Fengjun
    Ning, Siqing
    Zhou, Haibo
    Chen, Guiming
    Huang, Jing
    Peng, Gang
    Yang, Kunyu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345